Rongcan Biotech

Shanghai, China · Founded 2020 · Privately Held (backing)

Developer of mRNA-based pharmaceutical products designed for nucleic acid-based therapeutics. Rongcan Biotech is based in Shanghai, China and was founded in 2020. It has raised $13.8 million.

Last price · $/share
—
Implied valuation
—
Total raised
$13.8M
Last round
—
Valuation — not yet established

No valuation for Rongcan Biotech is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($13.8M) and the funding record below are the closest available signals.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Rongcan Biotech with a free account
  • ·Watch Rongcan Biotech: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Rongcan Biotech funding history

No rounds on record

No funding rounds for Rongcan Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

How Rongcan Biotech's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Rongcan Biotech, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about Rongcan Biotech

How much has Rongcan Biotech raised?
Rongcan Biotech has raised $13.8M in total funding across its recorded rounds.